Title:
ANTIGEN TARGETING, ANTI-CD16A, AND IMMUNE EFFECTOR CELL ACTIVATING TRIFUNCTIONAL FUSION PROTEIN, AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/006082
Kind Code:
A1
Abstract:
Disclosed is an antigen targeting, anti-CD16A, and immune effector cell activating trifunctional fusion protein, comprising: a CD16A binding region that specifically binds to CD16A, a tumor-associated antigen (TAA) binding region that specifically binds to a TAA, an IL-15/IL-15Rα complex formed by combining IL-15 and IL-15Rα, and an Fc domain. A designed tumor-targeting innate immune cell activation molecule, i.e., an anti-TAA, anti-CD16A, and cytokine IL15 trifunctional fusion protein targets NK cells to a tumor by simultaneously binding to a TAA on tumor cells and CD16A on NK cells, so that the NK cells release perforin and granzymes to induce apoptosis and cause tumor cell death. The cytokine IL15 expands and maintains the function of the NK cells, stimulates immune cell proliferation, and changes the immune microenvironment of the tumor.
Inventors:
QU XIANGDONG (CN)
PAN QIN (CN)
PAN QIN (CN)
Application Number:
PCT/CN2022/109039
Publication Date:
February 02, 2023
Filing Date:
July 29, 2022
Export Citation:
Assignee:
QURE BIOTECHNOLOGY SHANGHAI CO LTD (CN)
International Classes:
C07K16/46; A61K39/395; A61P35/00; C07K16/28; C07K16/30; C07K19/00; C12N15/13; C12N15/85
Foreign References:
| CN113135996A | 2021-07-20 | |||
| CN105367660A | 2016-03-02 | |||
| EP3091031A1 | 2016-11-09 | |||
| CN112119097A | 2020-12-22 | |||
| US20160355600A1 | 2016-12-08 | |||
| US20180291110A1 | 2018-10-11 | |||
| CN108264558A | 2018-07-10 | |||
| US20200148737A1 | 2020-05-14 |
Download PDF: